Cargando…

Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin

INTRODUCTION: A significant decrease in red blood cell (RBC) survival has been observed in patients with renal failure, which is supposed to contribute to renal anemia. The aim of this observational study was to determine RBC survival in hemodialysis (HD) patients treated with roxadustat or recombin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiaowei, Zhao, Bing, Wang, Jing, Wang, Lei, Tao, Min, Lu, Jing, Lin, Jiangong, Sun, Jing, Wang, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525968/ https://www.ncbi.nlm.nih.gov/pubmed/34657570 http://dx.doi.org/10.1080/0886022X.2021.1988968

Ejemplares similares

Effect of roxadustat on red blood cell lifespan in patients with long-term haemodialysis: a single-centre, prospective, single-arm study
por: Zhao, Bing, et al.
Publicado: (2023)

Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia
por: Xu, Bojun, et al.
Publicado: (2021)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
por: Yasuoka, Yukiko, et al.
Publicado: (2022)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
por: Zheng, Xiaomeng, et al.
Publicado: (2023)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis
por: Cheng, Shuiqin, et al.
Publicado: (2023)

Effect of Roxadustat versus erythropoietin (EPO) for treating anemia in patients with diabetic kidney disease: a retrospective cohort study
por: Zhang, Lei, et al.
Publicado: (2022)

Case Report: Roxadustat in Combination With Rituximab Was Used to Treat EPO-Induced Pure Red Cell Aplasia
por: You, Xiaoe, et al.
Publicado: (2022)

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study
por: Zhang, Yaling, et al.
Publicado: (2021)

Acquired Pure Red Cell Aplasia and Recombinant Erythropoietin
por: Padhi, Somanath, et al.
Publicado: (2021)

Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
por: Zhu, Xin-Wang, et al.
Publicado: (2021)

Comparison of risk of peritoneal dialysis-associated peritonitis between roxadustat and recombinant human erythropoietin in peritoneal dialysis patients: a retrospective comparative cohort study
por: Zhang, Wei, et al.
Publicado: (2022)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
por: Zhou, Qiaoqiao, et al.
Publicado: (2023)

Correlation between blood concentration of roxadustat and clinical efficacy in patients with anemia of chronic kidney disease
por: Zhang, Yanjing, et al.
Publicado: (2023)

Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature
por: Fei, Min, et al.
Publicado: (2021)

Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study
por: Jin, Chen, et al.
Publicado: (2022)

Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients
por: Rahbar, Maryam, et al.
Publicado: (2017)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis
por: Yoshida, Shunsuke, et al.
Publicado: (2023)

Efficacy and Safety of Roxadustat in Chinese Hemodialysis Patients: A Systematic Review and Meta-Analysis
por: Liang, Qichen, et al.
Publicado: (2023)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Association of short-term blood pressure variability with cardiovascular mortality among incident hemodialysis patients
por: Feng, Yiduo, et al.
Publicado: (2018)

Successful application of roxadustat in the treatment of patients with anti-erythropoietin antibody-mediated renal anaemia: a case report and literature review
por: Cai, Ke-Dan, et al.
Publicado: (2021)

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
por: Ichii, Mitsuru, et al.
Publicado: (2021)

Association between red blood cell distribution width and non-valvular atrial fibrillation in hemodialysis patients: a single-center Chinese population study
por: Zhang, Tao, et al.
Publicado: (2022)

Recombinant human erythropoietin α modulates the effects of radiotherapy on colorectal cancer microvessels
por: Ceelen, W, et al.
Publicado: (2007)

Comparison of Oral Recombinant Erythropoietin and Subcutaneous Recombinant Erythropoietin in Prevention of Anemia of Prematurity
por: Saeidi, R, et al.
Publicado: (2012)

Comparing the effects of intravenous and subcutaneous Erythropoietin on blood indices in hemodialysis patients
por: Ghasemi, Faramarz, et al.
Publicado: (2019)

Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS
por: Yu, Jing, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
por: Wu, Yunzhou, et al.
Publicado: (2020)

Calcium homeostasis in red blood cells of dialysis patients in dependence of erythropoietin treatment
por: Wang, Jue, et al.
Publicado: (2014)

Impact of inflammation on anemia of hemodialysis patients who were under treatment of recombinant human erythropoietin
por: Rafiean-Kopaie, Mahmoud, et al.
Publicado: (2013)

Recombinant human erythropoietin for treating severe traumatic brain injury
por: Bai, Xiao-Fei, et al.
Publicado: (2018)

Red blood cell distribution width as a marker of cerebral infarction in hemodialysis patients
por: Mo, Liyi, et al.
Publicado: (2017)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy
por: Padhi, Somanath, et al.
Publicado: (2020)

Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report
por: Zhou, Qiao-Qiao, et al.
Publicado: (2022)

Effect of Red Light Rhinophototherapy on Nasal Patency in Patients with Allergic Rhinitis
por: Jiang, Rong-San, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l2bb4657grnocj6cvasgb4egle